Acrivon Therapeutics (ACRV) to Release Earnings on Thursday

Acrivon Therapeutics (NASDAQ:ACRV) is anticipated to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.66) per share for the quarter.

Acrivon Therapeutics Stock Down 3.9 %

Acrivon Therapeutics stock opened at $5.39 on Wednesday. Acrivon Therapeutics has a twelve month low of $4.69 and a twelve month high of $11.90. The company has a 50 day moving average of $5.54 and a 200-day moving average of $6.63. The stock has a market capitalization of $167.82 million, a PE ratio of -2.00 and a beta of 0.85.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ACRV. KeyCorp started coverage on shares of Acrivon Therapeutics in a research report on Friday, January 31st. They issued an “overweight” rating on the stock. Cantor Fitzgerald initiated coverage on shares of Acrivon Therapeutics in a report on Friday, January 31st. They set an “overweight” rating for the company. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $23.67.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.